High-grade prostate cancer accompanied by multiple bone metastases-05

The patient, a 67-year-old male, was diagnosed with high-grade prostate cancer accompanied by multiple bone metastases. Initial diagnosis indicated that the tumor was highly aggressive and could not be completely removed surgically. Despite undergoing radiation and chemotherapy, the tumor continued to spread to surrounding tissues and responded poorly to treatment.

Given the limitations of traditional treatments and the patient's health condition, he opted to participate in a clinical trial for NK (Natural Killer) cell therapy. The treatment plan began with the first course in February 2023, followed by maintenance therapy every six months. Each session involved the reinfusion of immune cells via intravenous infusion to enhance the patient's immune system in combating the tumor.

After the first course of NK cell therapy, the patient reported initial signs of pain relief and improved quality of life. His physical performance scores increased, and his mental state showed significant improvement.

Following the second course of treatment, a PET-CT scan evaluation was conducted. The scan results indicated a significant reduction in metabolic activity in both the primary prostate tumor and bone metastases, with some lesions showing complete regression. The tumor burden was markedly reduced, confirming the effectiveness of the treatment.

To date, the patient's quality of life has significantly improved, and his symptoms are well-controlled with no signs of local tumor recurrence. He continues to undergo regular follow-up and treatment monitoring to ensure the sustained efficacy and further improvement of his condition.

Supported by NK cell therapy, the patient's condition has notably improved, providing strong support and encouragement for further exploration and application of immunotherapy in prostate cancer patients.